Checkpoint Inhibitors Under Exploration in RCC

Video

For High-Definition, Click

There are several early phase clinical trials assessing PD-1 inhibitors for patients with renal cell carcinoma, notes Nicholas J. Vogelzang, MD. At this point, a clear leader has not yet emerged. Genentech is currently exploring bevacizumab plus their PD-L1 inhibitor MPDL3280A. Additionally, BMS has an advantage by marketing both nivolumab and ipilimumab. With all of the agents under exploration, it is a good time for referring patients to clinical trials, Vogelzang adds.

Related Videos
Thomas F. Gajewski, MD, PhD
Michelle Krogsgaard, PhD
D. Ross Camidge, MD, PhD
D. Ross Camidge, MD, PhD
D. Ross Camidge, MD, PhD
Manmeet Singh Ahluwalia, MD
D. Ross Camidge, MD, PhD
D. Ross Camidge, MD, PhD
Sangeeta Goswami, MD, PhD, of The University of Texas MD Anderson Cancer Center